Table 2

Three and 12 months follow-up data (corrected for baseline differences)

MeasureIntervention group
(n=36)
Control group
(n=44)
Difference between the intervention and control group controlling for baseline (95% CI)
M (SD)%>MCID*
improvement
% items completeM (SD)%>MCID* improvement% items complete
3 months
 AQLQ5.51 (0.85)47.2825.30 (1.07)47.71000.06 (−0.22 to 0.35)
 ACQ0.98 (0.65)821.28 (0.87)100−0.14 (−0.41 to 0.13)
 HADS-A6.75 (3.85)827.07 (5.48)100−0.04 (−0.18 to 0.11)
 HADS-D3.75 (2.82)824.66 (4.99)100−0.02 (−0.16 to 0.13)
 PEI2.71 (1.09)822.90 (1.14)100−0.12 (−0.59 to 0.35)
 MARS-A4.23 (0.70)804.05 (0.74)1000.04 (−0.25 to 0.3)
 EQ-5D-5L0.82 (0.19)820.83 (0.20)100
 ICECAP-A0.87 (0.12)820.84 (0.19)100
12 months
 AQLQ5.29 (0.98)38.9825.00 (1.25)39.5980.18 (−0.21 to 0.56)
 ACQ1.00 (0.59)821.26 (0.69)98−0.14 (−0.40 to 0.11)
 HADS-A7.78 (3.94)846.63 (4.91)980.99 (0.16 to 2.15)
 HADS-D3.81 (3.54)844.19 (4.17)980.22 (−0.97 to 1.41)
 PEI2.46 (1.03)842.61 (1.28)98−0.09 (−0.54 to 0.37)
 MARS-A4.37 (0.81)824.29 (0.85)98−0.09 (−0.43 to 0.25)
 EQ-5D-5L0.83 (0.21)820.80 (0.23)98
 ICECAP-A0.86 (0.13)820.84 (0.20)98
 FEV1 (litres)2.75 (0.75)572.43 (0.74)800.03 (−0.05 to 0.10)
 FEV1/FVC78.8 (6.58)5776.3 (9.29)802.20 (−0.13 to 4.27)
% predicted FEV1 100.1 (14.8)5792.4 (13.8)801.77 (−1.72 to 5.25)
Peak flow450 (105)57417 (102)8015.29 (−6.27 to 36.86)
 BMI28.7 (6.17)6431.1 (6.51)86−0.11 (−0.89 to 0.68)
  • *There was no difference in the number of patients who showed MCID improvement at 3 months (AQLQ, >0.5) across groups (47.2% in the intervention group compared with 47.7% in the control group). The same was true at 12 months (38.9% compared with 39.5%).

  • ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; EQ-5D-5L, EuroQol Five Dimensional Quality of Life; FEV1, forced expiratory volume; FVC, forced vital capacity; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; ICECAP-A, Icepop Capability measure for Adults; MARS-A, Medication Adherence Rating Scale for Asthma; MCID, minimal clinically important difference; PEI, patient enablement instrument.